The anti-leukemic efficacy of the third generation bisphosphonate ONO5920/YM529.
Leuk Res
; 29(4): 451-7, 2005 Apr.
Article
in En
| MEDLINE
| ID: mdl-15725480
ABSTRACT
Ras proteins are frequently over-expressed in leukemia and contribute to leukemogenesis. We evaluated the anti-leukemic efficacy of a new third-generation bisphosphonate, ONO5920/YM529 (YM529). YM529 prevents the prenylation of Ras proteins and inhibited the growth of leukemic cells including a P-glycoprotein (P-gp) over-expressing cell line in a concentration- and time-dependent manner by inducing apoptosis in vitro. Moreover, YM529 synergistically augmented the anti-leukemic activities of paclitaxel and daunorubicin in vitro. Importantly, YM529 prolonged the survival of NOD/SCID mice engrafted with human primary leukemic cells. These findings indicate that the YM529 may become a novel molecular therapeutic class for treatment of leukemias.
Search on Google
Database:
MEDLINE
Main subject:
Leukemia
/
Diphosphonates
/
Imidazoles
/
Antineoplastic Agents
Limits:
Animals
/
Humans
Language:
En
Year:
2005
Type:
Article